LH
Labcorp Holdings Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -0.9% · net new positions -5.3% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 88.13K | $17.42M | n/a | n/a |
| Q2 2026 | 156 | +5 | 55.88M | $15.63B | +9 | −5 |
| Q1 2026 | 155 | +1 | 55.32M | $14.74B | +4 | −4 |
| Q4 2025 | 153 | -1 | 61.82M | $15.50B | +1 | −1 |
| Q3 2025 | 19 | 0 | 33.10M | $9.50B | n/a | −1 |
| Q2 2025 | 17 | -1 | 30.31M | $7.95B | +1 | −2 |
| Q1 2025 | 15 | +2 | 7.94M | $1.85B | +2 | n/a |
| Q4 2024 | 13 | 0 | 9.58M | $2.20B | +2 | −2 |
| Q3 2024 | 12 | +1 | 4.32M | $962.67M | +2 | −1 |
| Q2 2024 | 11 | n/a | 5.93M | $1.21B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 9.81M | -0.7% | $2.82B | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passive) | 8.13M | -10.3% | $2.33B | 0.0% | ▼ Trim | 2 | SEC ↗ ×20 |
| 3 | State Street Global Advisors ✦ (passive) | 3.83M | -0.8% | $1.10B | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | JPMorgan Chase ✦ | 2.15M | n/a | $616.63M | 0.0% | n/c | 1 | SEC ↗ ×30 |
| 5 | Geode Capital Management ✦ (passive) | 2.12M | +0.5% | $606.94M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Wellington Management ✦ | 2.11M | +15.9% | $604.49M | 0.1% | ▲ Add | 6 | SEC ↗ ×8 |
| 7 | Morgan Stanley ✦ | 1.51M | n/a | $432.71M | 0.0% | n/c | 1 | SEC ↗ ×17 |
| 8 | Fidelity (FMR) ✦ | 1.45M | -13.5% | $415.73M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 9 | Marshall Wace ✦ | 623.55K | +79.1% | $179.00M | 0.2% | ▲ Add | 3 | SEC ↗ ×3 |
| 10 | Citadel Advisors ✦ | 516.55K | +268.3% | $148.28M | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 11 | Goldman Sachs Group ✦ | 422.15K | n/a | $121.18M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 12 | AQR Capital Management ✦ | 163.33K | +4.2% | $46.42M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 13 | T. Rowe Price ✦ | 120.19K | -0.3% | $34.50M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | Gotham Asset Management ✦ | 95.03K | +39.2% | $27.28M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 15 | Adage Capital Partners ✦ | 23.70K | 0.0% | $6.80M | 0.0% | Held | 4 | SEC ↗ |
| 16 | Millennium Management ✦ | 10.70K | -35.5% | $3.07M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 17 | Bridgewater Associates ✦ | 10.39K | +275.1% | $2.98M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 5.31K | -76.3% | $1.52M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Fisher Asset Management ✦ | 1.73K | +4.2% | $496,671 | 0.0% | ▲ Add | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Norges Bank | $263.07M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,014 holders, 76.41M shares, $19.36B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 3.00K sh · $954,060
Officer, Director · 4.67K sh · $1.50M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology